Details
Stereochemistry | ACHIRAL |
Molecular Formula | H3O4P |
Molecular Weight | 98.9953 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O[32P](O)(O)=O
InChI
InChIKey=NBIIXXVUZAFLBC-HOSYLAQJSA-N
InChI=1S/H3O4P/c1-5(2,3)4/h(H3,1,2,3,4)/i5+1
P-32 is a radioactive isotope of phosphorus with a half-life of 14.29 days. Radioactive decay of P-32 produces beta-particles (electrons) which are able to penetrate tissue at a range of 3-8 mm. Phosphate ion P-32 has many applications in medicine and biology. P32 sodium phosphate was approved by the FDA for the treatment of polycythemia vera, chronic myelocytic leukemia, and chronic lymphocytic leukemia. P32-phosphate may also be used in the palliative treatment of selected patients with multiple areas of skeletal metastases. As metabolic uptake of phosphorus is selectively increased in malignant tissues, P-32 was also used for cancer diagnostics.
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | SODIUM PHOSPHATE P 32 Approved UseP32 sodium phosphate is indicated for the treatment of polycythemia vera and is effective for the treatment of chronic myelocytic leukemia and chronic lymphocytic leukemia. It may also be used in the palliative treatment of selected patients with multiple areas of skeletal metastases Launch Date1959 |
|||
Primary | SODIUM PHOSPHATE P 32 Approved UseP32 sodium phosphate is indicated for the treatment of polycythemia vera and is effective for the treatment of chronic myelocytic leukemia and chronic lymphocytic leukemia. It may also be used in the palliative treatment of selected patients with multiple areas of skeletal metastases Launch Date1959 |
|||
Primary | SODIUM PHOSPHATE P 32 Approved UseP32 sodium phosphate is indicated for the treatment of polycythemia vera and is effective for the treatment of chronic myelocytic leukemia and chronic lymphocytic leukemia. It may also be used in the palliative treatment of selected patients with multiple areas of skeletal metastases Launch Date1959 |
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
N9H3ZTX0BG
Created by
admin on Sat Dec 16 00:28:20 GMT 2023 , Edited by admin on Sat Dec 16 00:28:20 GMT 2023
|
PRIMARY | |||
|
15364-02-0
Created by
admin on Sat Dec 16 00:28:20 GMT 2023 , Edited by admin on Sat Dec 16 00:28:20 GMT 2023
|
PRIMARY | |||
|
71181
Created by
admin on Sat Dec 16 00:28:20 GMT 2023 , Edited by admin on Sat Dec 16 00:28:20 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD